Joshua Raskin Barclays Capital
Joshua Raskin, who spent last year in third place, reclaims the No. 2 spot he held from 2005 through 2008. The Barclays Capital analyst upgraded HealthSpring of Franklin, Tennessee, from neutral to buy in January, at $18.52, on improving profitability. The stock had advanced 12.1 percent, to $20.76, by the end of August. “HealthSpring was a great call for us — Raskin made us money on that stock,” cheers one appreciative buy-sider.